

# Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis

Ji Wang  
Chengchu Zhu

Department of Cardiothoracic Surgery, Taizhou Hospital, Wenzhou Medical University, Linhai, Zhejiang, People's Republic of China

**Abstract:** Hypercoagulable state and disorganized angiogenesis are two conspicuous characteristics during tumor progression. There are a considerable number of clinical trials focusing on the effects of anticoagulant and antiangiogenic drugs on the survival of cancer patients. Favorable outcomes have been observed. Excessive blood coagulation not only causes cancer-associated thrombosis, which is a common complication and is the second leading cause of death in patients, but also decreases intratumoral perfusion rates and drug delivery by reducing the effective cross-sectional area of blood vessels. Meanwhile, structural and functional abnormalities of the tumor microvasculature also compromise convective drug transport and create a hypoxic and acidic microenvironment. Vascular normalization strategy can temporarily recover the abnormal state of tumor vasculature by improving blood density, dilation, and leakiness, resulting in enhanced penetration of chemotherapies and oxygen within a short time window. In this article, we first review the evidence to support the opinion that anticoagulant and antiangiogenic therapy can improve cancer survival through several underlying mechanisms. Next, we speculate on the feasibility and value of the combined strategy and discuss whether such a combination has a synergistic antineoplastic effect in cancer patients by way of increasing blood vessel perfusion and drug distribution.

**Keywords:** tumor microenvironment, anticoagulation, antiangiogenesis, vascular normalization, tumor perfusion

## Introduction

Since the French physician Armand Trousseau first described the occurrence of thromboembolic disease in cancer patients nearly 150 years ago, the close relationship between malignancy and excessive blood coagulation has slowly become well recognized. The hypercoagulable state is a universal phenomenon in malignant tumors, which not only seriously impacts local tumor microenvironment but also leads to systemic venous and arterial thrombosis.<sup>1,2</sup> Beyond biological factors, clinical factors, such as bed rest, chemoradiotherapy, central venous catheters, infection, and surgery, are all contributory causes that will determine whether an asymptomatic phenotype manifests clinically.<sup>3</sup> In fact, >90% of cancer patients commonly present with various signs and symptoms of the prothrombotic state that range from one or more asymptomatic coagulation indicators, to clinically defined thromboembolism and disseminated intravascular coagulation.<sup>4</sup> A growing body of studies have proposed that thrombosis is a common complication of malignancy that provokes disease progression and poor prognosis, interferes with patients' quality and expectancy of life, and increases health care costs considerably.<sup>5,6</sup> Hence, anticoagulant therapy

Correspondence: Chengchu Zhu  
Department of Cardiothoracic Surgery,  
Taizhou Hospital, Wenzhou Medical  
University, 150 Ximen Road, Linhai,  
Zhejiang 317000, People's Republic of  
China  
Tel +86 182 6761 2279  
Email wangji881019@163.com

plays an important role in tumor treatment, even in patients with advanced disease.

During tumor progression, aberrant angiogenesis is another significant feature. Formation of a new vascular network or development of a preexisting vascular bed is initiated by the well-known angiogenesis inducer vascular endothelial growth factor (VEGF). The binding of VEGF to VEGF receptor (VEGFR) stimulates autophosphorylation in certain tyrosine residues. The signal activates downstream pathways and regulates endothelial cell survival and proliferation.<sup>7</sup> Thus, targeting the VEGF–VEGFR pathway has become a considerable therapeutic strategy for cancer treatment. Presently, three primary pharmacological strategies targeting angiogenesis have been created in cancer therapy: 1) the monoclonal antibodies (moAbs) binding VEGF directly such as the anti-VEGF antibody bevacizumab; 2) targeting angiogenesis receptors either with moAbs such as the anti-VEGFR2 antibody or with the inhibitors of tyrosine kinase receptors such as sunitinib and sorafenib; and 3) inhibiting VEGF signaling by recombinant receptor–antibody fusion proteins such as aflibercept.<sup>8</sup> Nevertheless, the fundamentals of these antiangiogenic drugs has not been determined conclusively to this day.

We first summarize the recent studies of tumor microenvironment, including both hypercoagulability and abnormal angiogenesis, in cancer. Next, we elaborate on current clinical evidence and several underlying mechanisms of anticoagulant and antiangiogenic therapy during tumor progression. Finally, we hypothesize whether both the important treatment strategies have a synergistic antineoplastic effect in clinical application that improves the prognosis of the patients, especially by increasing blood vessel perfusion and drug distribution. Furthermore, we give future perspectives in the field of coagulation and angiogenesis in cancer.

## Anticoagulant therapy

The association between anticoagulant therapy and tumor disease progression is controversial. Data from different randomized clinical trials suggest a conflicting outcome of low-molecular weight heparin (LMWH) on survival in patients with several types of cancer (Table 1). Therapeutic effects of LMWH display a moderate impact on certain types of cancers, such as small-cell lung cancer.<sup>9–11</sup> It possibly implies that small-cell lung cancer is more sensitive than other cancer types for LMWH treatment. In addition, researchers also notice that LMWH appears to be more effective in patient populations with limited-stage disease, or with

a longer estimated life expectancy.<sup>10–12</sup> This may explain the poor results that frustrated researchers on clinical trials that recruited more patients with metastatic or locally advanced cancer. These participants might not theoretically benefit from any antineoplastic effects of LMWH. Despite the fact that the benefit of LMWH therapy on cancer patients' survival is still inconclusive, it is surely associated with a clinically significant reduction in venous thromboembolic event (VTE). Accordingly, with enough consideration in terms of cancer type and stage, anticoagulant therapy, especially LMWH, is a remarkable adjunctive therapy for cancer patients. It is worth noting that these beneficial influences are not completely explained by the prevention and treatment of thrombosis. Several possible interrelated pathology mechanisms have been raised by researchers, including both coagulation-dependent and coagulation-independent activities.

## Prevention and treatment of cancer-associated thrombosis

Cancer-associated thrombosis is a prevalent complication in tumor progression and is associated with a poor prognosis.<sup>13</sup> It is estimated consistently that cancer is related to 20%–30% of all first VTE.<sup>14</sup> Due in part to increasing cancer prevalence, improved oncology outcomes, and the use of more effective but prothrombotic therapy regimens (ie, chemotherapy, radiotherapy, hormone therapy, angiogenesis inhibitors, and surgery), a steady increase in the incidence of cancer-associated thrombosis has been observed, during the past 2 decades.<sup>15</sup> Although both venous and arterial thrombosis can be established in cancer patients, the venous thrombotic occlusions have been studied more extensively, including deep venous thrombosis and pulmonary embolism. A retrospective cohort study of over a million inpatients with cancer found an overall prevalence VTE rate of 4.1%, with prevalence incidence enhanced by 28% from 1995 to 2003.<sup>16</sup> A recent systematic review on the absolute risk of VTE in cancer patients found an overall VTE incidence rate of 43 per 1,000 person-years, with a fourfold increased risk compared with the patients with no malignancy.<sup>17</sup> VTE can occur in throughout the cancer process, especially in the first few months after the diagnosis of cancer.<sup>18</sup> Furthermore, thrombotic events are the second most common cause of death in patients with cancer, ranking after death from the cancer itself. Thrombotic event explains 9% of cancer-related deaths, at a high cost to patients and society.<sup>19,20</sup> Accordingly, given the high incidence and mortality, prevention and management of thrombotic events in cancer patients are extremely urgent. Many guidelines

**Table I** Overview of randomized clinical trials of LMWHs on survival of cancer patients

References	Cancer type	Heparin (number of patients)	Regimen	Effect on survival
Kakkar et al <sup>10</sup>	Advanced cancer (breast, colorectal, ovarian, and pancreatic)	Dalteparin (385)	5,000 IU/d, 1 year	Significant increase in median survival in patients with better prognosis (43.5 months vs 24.3 months; $P=0.03$ )
Altinbas et al <sup>9</sup>	Small-cell lung cancer	Dalteparin (84)	5,000 IU/d, 18 weeks	Significant increase in median survival (13 months vs 8 months; $P=0.01$ )
Klerk et al <sup>69</sup>	Metastasized and advanced cancer (breast, lung, GIT, pancreas, renal, ovary, uterus)	Nadroparin (302)	Therapeutic dose 2 weeks + half dose 4 weeks	Significant increase in median survival in patients with better prognosis (15.4 months vs 9.4 months; $P=0.01$ )
van Doormaal et al <sup>70</sup>	Non-small-cell lung cancer, prostate, pancreatic	Nadroparin (503)	Therapeutic dose 2 weeks + half dose 4 weeks	Median survival 11.9 months (placebo) versus 13.1 months (LMWH)
Agnelli et al <sup>71</sup>	Colorectal and lung	Semuloparin (3,212)	20 mg/d, 3.5 months	1-year survival rate 55.5% (placebo) versus 56.6% (LMWH)
Lecumberri et al <sup>11</sup>	Limited small-cell lung cancer	Bemiparin (38)	3,500 IU/d, 26 weeks	Median progression-free survival 272 days (placebo) versus 410 days (LMWH), $P=0.022$ Median overall survival was 345 days (placebo) versus 1,133 days (LMWH), $P=0.017$
Lebeau et al <sup>12</sup>	Small-cell lung cancer	Unfractionated heparin (277)	500 U/kg/d, 5 weeks	Significant increase in median survival (317 days vs 261 days; $P=0.01$ ); response rates (23% vs 37%; $P=0.004$ ) At subgroup analysis, the results on survival were obtained for limited diseases ( $P=0.03$ ) but not for extensive diseases ( $P=0.31$ )

**Abbreviations:** LMWH, low molecular weight heparin; GIT, gastrointestinal tract.

have been published from international scientific societies. The American Society of Clinical Oncology and the National Comprehensive Cancer Network guidelines suggested that prophylaxis with anticoagulant drug is recommended for inpatients with cancer in the absence of bleeding or other contraindications to anticoagulant. By contrast, the European Society of Medical Oncology and American College of Chest Physicians requires bedridden hospital cancer patients with an acute medical complication to be considered for medical thromboprophylaxis in the form of low-dose unfractionated heparin or LMWH. Numerous guidelines acknowledge the significant incidence of VTE in cancer patients undergoing surgery, and recommend surgical patients receive perioperative VTE prophylaxis, although the specific anticoagulant scenarios differ slightly among them.<sup>21–24</sup> Based on the results of several randomized controlled trials and meta-analyses, the use of LMWH is preferred over other anticoagulants in most cases in cancer patients treated for VTE.<sup>25</sup> LMWH is characterized by: lower time for coagulation monitoring, fewer major bleeding events, and once-daily dosing, which make these drugs more appropriate for cancer therapy.<sup>26,27</sup> Fondaparinux is also an acceptable agent for use in initial

treatment.<sup>28</sup> Furthermore, aspirin has been shown to hinder arterial thrombosis and to reduce the rate of major vascular events, but there are less data supporting the benefits of therapeutic antiplatelet agents at preventing VTE in cancer patients as well.<sup>29,30</sup>

## Anticancer effects

The pathogenesis of the coagulation system imbalance in cancer is likely to be multifactorial, including both coagulation-dependent and -independent activities. A change in the coagulation system itself may conduce the hypercoagulable state. Tumor-specific prothrombotic mechanisms also play a significant role in the complex process. Malignant cells can influence the expression and release of procoagulant factors (ie, tissue factor and cancer procoagulant), inflammatory cytokines, and circulating microparticles, and then activate host coagulation system. The direct stimulation of blood cells, including endothelial cells, platelets, and monocytes, also causes confusion of the hemostatic system;<sup>31,32</sup> vice versa, the disorder of coagulation is closely linked to tumor progression and metastasis as well. Thrombin enlarges cancer cell binding to platelets and

upgrades the metastasizing ability of cancer cells efficaciously in experimental pulmonary metastasis models.<sup>33</sup> In addition, lowering endogenous activated protein C levels will contribute to enhanced metastasis in hypercoagulable mice.<sup>34</sup> Since the first exploration of a potential beneficial antineoplastic effects of anticoagulant drugs was found in 1930, studies have actively investigated how the anticoagulant drugs affect tumor growth and metastasis through multiple mechanisms.<sup>35</sup> Many findings demonstrated that anticoagulants, in particular the LMWH, can affect the growth of primary tumors, block tumor cell heparanase, suppress selectin-mediated tumor cell invasion and metastasis, and inhibit tumor-induced angiogenesis in both in vivo and in vitro systems.<sup>36–39</sup> In addition, the use of aspirin as a cancer chemopreventive agent has a long history of clinical use. Although the antineoplastic effects of aspirin have not been well explained, emerging clinic evidence has shown that constant use of aspirin effectively improves cancer patients' prognosis, particularly those with colorectal cancer.<sup>40</sup> A randomized trial of 311 patients with colorectal adenomas and adenocarcinomas excised by endoscopy showed that the subjects treated with aspirin exhibited lower colorectal tumorigenesis and primary end points with an adjusted odds ratio of 0.60 compared with the subjects in the placebo group.<sup>41</sup> Warfarin, a kind of coumarin anticoagulant, has been known to reduce tumor metastases in mouse and rat models. But the potential mechanisms were mostly ambiguous. Recently, the study by Paolino et al<sup>42</sup> supported a coagulation-independent role of warfarin in tumor metastasis that relies on its inhibitory effect on the Cbl-b/TAM receptors in natural killer cells. It once again raised a major concern regarding the antimetastatic activity of warfarin in cancer treatment. Altogether, these preclinical studies and clinical data further contribute to supporting the proof of potential antineoplastic effects of anticoagulants. It is highly desirable that anticoagulants serve as an adjuvant therapy for cancer treatment in the future.

## Increasing blood vessel perfusion and drug penetration

The influence of hypercoagulable state that hamper vessel perfusion is constantly overlooked. It could hamper blood flow in a multitude of ways. On one hand, fibrin and other plasma proteins deposited within the tumor vasculature produce a physiological barrier that reduces the effective cross-sectional area of tumor blood vessels. While on the other hand, tumors are inevitably concomitant with blood capillary ruptures and hemorrhage, resulting in blood leaking into the extracellular matrix, which becomes extravascular

thrombosis. Extravascular thrombosis is a mechanical force that generates vessel compression and thus inhibits convective blood flow.<sup>36,43</sup> Therefore, we assume that anticoagulant drugs improve tumor aberrant blood flow in favor of raising the effective concentration of chemotherapeutics in tumor tissue and forming closer contacts between chemotherapeutic agents and tumor cells, which ensures a better therapeutic efficacy. Phillips et al<sup>44</sup> conducted biodistribution studies to determine the effect of LMWH on uptake of paclitaxel (PACL) and doxorubicin (Dox) by breast tumor xenografts. In the MDA453/LCC6 breast tumor xenograft model, they confirmed that LMWH conducts greater [<sup>124</sup>I]-PACL intratumoral concentration than that of [<sup>124</sup>I]-PACL alone. Similarly, LMWH significantly increased the uptake of Dox in MCF7 Dox-resistant tumor xenografts by 1.5- to 2-fold. Importantly, although LMWH compounds selectively increased tumor uptake of Dox, the drug accumulation in heart and lung tissues, both sites of serious toxicity with this drug, were not increased but reduced. This study credibly demonstrated that LMWH administration considerably improves the efficient distribution of chemotherapeutics and overcomes tumor chemoresistance. The secondary application of anticoagulant drugs might also decrease the doses of chemotherapy required due to more efficient delivery into intratumoral region.<sup>44</sup> The possible mechanisms that explain the improvement of tumor uptake of chemotherapy agents may be complex. As stated earlier, LMWH reduces the deposition of fibrin and other plasma proteins in the blood vessel wall and the extravascular thrombosis, which reopens restricted vessels in the tumor microenvironment. Thus, LMWH and other anticoagulants may overcome the physical barrier and relieve the viscid blood flow by decreasing clotted sediments. This potential effect of anticoagulants is worth exploring thoroughly in further studies, and more direct evidence would likely increasingly support the paradigm.

## Antiangiogenic therapy

Angiogenesis, a conspicuous hallmark of malignancy, promotes tumor growth and metastasis by transferring oxygen and nutrients into the tumor mass.<sup>45</sup> In contrast to the healthy vasculature that was arranged in a coherent style, tumor vessels are aberrant in almost all aspects of their structure and function at macroscopic and microscopic levels. The dysfunctional vessels are commonly organized in a more dilated and tortuous shape, and the hyperpermeable vessels with large gaps between endothelial cells, isolated pericytes, and discontinuous or absent basement membranes.<sup>46</sup> A large

quantity of blood plasma leaks into the tumor interstitial space due to the leaky vascular wall, which enhances local interstitial fluid pressure, red blood corpuscle concentration, and blood viscosity.<sup>47</sup> This greatly decreases the blood velocity in focal vascular sections and diverts blood flow to other sites. The abnormal vasculature leads to a hostile tumor microenvironment. It not only reduces tumor blood perfusion but also converts the tumor into an unfavorable hypoxic and acidic microenvironment that diminishes tumor responsiveness to treatments. These pathophysiological characteristics compromise convective transport of drug and impede the effectiveness of conventional anticancer treatments as well as the function of immune cells in tumors.<sup>48–50</sup>

In 1971, Judah Folkman first articulated that antiangiogenic therapy is a promising strategy for cancer and initiated the isolation of tumor angiogenesis factors.<sup>51</sup> The discovery of VEGF as a major regulator of endothelial cell growth and survival paved the way for translating the idea into clinical practice.<sup>52</sup> In 2004, bevacizumab, a humanized moAb directed against VEGF, was approved by the US Food and Drug Administration as first-line treatment for metastatic colorectal cancer, in combination with conventional chemotherapy.<sup>53</sup> The validation of the first antiangiogenic drug opened a new chapter in the development of targeted therapy. Numerous antiangiogenic drugs have been gradually applied to several tumor types over the past 11 years, in particular targeting the VEGF–VEGFR signaling axis.<sup>54</sup> The introduction of these innovative drugs for oncotherapy has resulted in moderate improvements in tumor response and progression-free survival, or overall survival of cancer patients (Table 2). Undoubtedly, the benefits in these randomized trials are not universal, most probably due to heterogeneity of tumor type and therapeutic regimen. Also, antiangiogenic agents are typically given to unselected patients for the approved indications. It is highly desirable to identify reliable predictive markers to select homogeneous groups for more clinical trials.

Although the improved effect has been shown in various tumor types, the principal mechanism of VEGF-targeted drugs has not been explained well to this day. It is credible that different mechanisms have a more or less significant role depending tumor type. Clinical studies have demonstrated that distinct tumor types showed inconsistent responses to different types of VEGF inhibitors or combination regimens. VEGF inhibitors are active as single agents in renal cell carcinoma, hepatocellular carcinoma, and ovarian and neuroendocrine tumors.<sup>55</sup> In these tumors, the original theory of VEGF-targeted drugs may become predominant. The classic concept was that VEGF-targeted therapy can block tumors' blood

supply, then reduce the delivery of oxygen and fundamental nutrients, and finally arrest the previously uninhibited tumor cell growth.<sup>56</sup> In contrast, for other tumors such as colorectal cancer (CRC), non-small-cell lung cancer, and breast cancer (although this efficacy is currently pending),<sup>55</sup> VEGF inhibitors are effective only when combined with cytotoxic chemotherapy, seemingly contradicting the initial principal mechanism claims. According to the classical scenario, such suppressive angiogenesis generates spatial and temporal inadequacies of blood perfusion and restrains the intratumoral delivery of coadministered drugs. Moreover, enhanced hypoxia conditions caused by the antivascular effects also render tumor cells relatively chemoradiotherapy resistant and even become more aggressive.<sup>57</sup> Accordingly, given the complexity of tumor biology, such as the heterogeneity of blood vessel growth in different stages and locations, it would be unwise to attribute a single mechanism to VEGF inhibitors in multiple tumor types. In 2001, it has been proposed first that treatment with judicious antiangiogenic agents can transiently revert the abnormal tumor vasculature toward a relatively normal status. Antiangiogenic drugs selectively prune immature blood vessels and retain relatively mature vasculature.<sup>58</sup> The favorable phenomenon, vascular normalization, remodels tumor vessels that show improved connections between adjacent endothelial cells, enhanced pericyte coverage, and tighter association between them.<sup>59</sup> These physiological changes would reduce vascular permeability and result in a drop of intratumoral interstitial fluid pressure.<sup>60</sup> The increase of tumor blood perfusion improves oxygenation and drug delivery and thus inevitably makes tumors more sensitive to chemoradiotherapy.<sup>61</sup> Recently, with positron emission tomography imaging, Chatterjee et al<sup>62</sup> demonstrated that transient antiangiogenic treatment using potent VEGFR/platelet-derived growth factor receptor inhibitor PTK787 produces a transient time window of improved tumor blood flow with reduced leakiness and improved pericyte coverage. This short-lived normalization window results in improved outcomes of erlotinib administration.<sup>62</sup> Similarly, Batchelor et al<sup>63</sup> applied magnetic resonance imaging techniques and blood biomarkers in prospective Phase II clinical trials to show that the addition of cediranib, a pan-VEGFR tyrosine kinase inhibitor, to chemoradiation improved vascular integrity and blood perfusion in 20 of 40 (50%) newly diagnosed glioblastoma patients, compared with only one of 14 (7%) patients treated with conventional chemoradiation alone, and was associated with improved tumor oxygenation status. Of note, these newly diagnosed glioblastoma patients with improved tumor blood perfusion and oxygenation status after



**Table 2** Chemotherapy in combination with antiangiogenic agents in randomized trials in various malignancies


References	Tumor type	Regimen (number of patients)	PFS (months)	OS (months)
Saltz et al <sup>72</sup>	CRC	FOLFOX-4/XELOX + bevacizumab (701)	9.4 versus 8.0 (HR =0.83; P=0.0023)	21.3 versus 19.9 (HR =0.89; P=0.0769)
Giantonio et al <sup>73</sup>		FOLFOX-4/XELOX + placebo (699)	7.3 versus 4.7 (HR =0.61; P<0.0001)	12.9 versus 10.8 (HR =0.75; P=0.0011)
Van Cutsem et al <sup>74</sup>		FOLFOX-4 + bevacizumab (290)	6.9 versus 4.67 (HR =0.758; P=0.00007)	13.5 versus 12.06 (HR =0.817; P=0.0032)
Tabernero et al <sup>75</sup>		FOLFIRI + placebo (612)	5.7 versus 4.5 (HR =0.793; P<0.0005)	13.3 versus 11.7 (HR =0.884; P=0.0219)
Sandler et al <sup>76</sup>		FOLFIRI + ramucirumab (536)	6.2 versus 4.5 (HR =0.66; P<0.001)	12.3 versus 10.3 (HR =0.79; P=0.003)
Reck et al <sup>77</sup>		CbP + bevacizumab (434)	6.7 versus 6.5 versus 6.1 (HR =0.75; P=0.0026; 7.5 mg) (HR =0.82; P=0.03; 15 mg)	NA
Barlesi et al <sup>78</sup>		CbP (444)	3.7 versus 7.4 (HR =0.48; P<0.001)	NA
Zhou et al <sup>79</sup>		CG + bevacizumab (345)	9.6 versus 6.5 (HR =0.40; P<0.001)	24.3 versus 17.7 (HR =0.68; P=0.0154)
Pujade-Lauraine et al <sup>80</sup>		CG + bevacizumab (351)	6.7 versus 3.4 (HR =0.48; P<0.001)	NS
Aghajanian et al <sup>81</sup>		CG + placebo (347)	12.4 versus 8.4 (HR =0.484; P<0.0001)	NS
Ohtsu et al <sup>82</sup>	GC/GEJ	Bevacizumab (125)	6.7 versus 5.3 (HR =0.80; P=0.0037)	12.1 versus 10.1 (HR =0.87; P=0.1002)
Wilde et al <sup>83</sup>		Bevacizumab + pemetrexed (128)	4.4 versus 2.9 (HR =0.635; P<0.0001)	9.6 versus 7.4 (HR =0.807; P=0.017)
		CbP + bevacizumab (138)		
	ROC	CbP (138)		
		Paclitaxel + PLD/topotecan + bevacizumab (179)		
		Paclitaxel + PLD/topotecan (182)		
	GC/GEJ	GC + bevacizumab (242)		
		GC + placebo (242)		
		Fluoropyrimidine–cisplatin + bevacizumab (387)		
	GC/GEJ	Fluoropyrimidine–cisplatin + placebo (387)		
		Paclitaxel + ramucirumab (330)		
		Paclitaxel + placebo (335)		

**Abbreviations:** CRC, colorectal cancer; NSCLC, non-small-cell lung cancer; ROC, recurrent ovarian, primary peritoneal, or fallopian tube cancer; GC/GEJ, gastric cancer/cancers of the distal esophagus and gastroesophageal junction; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; OS, overall survival; NS, not significant; NA, not available; HR, hazard ratio; CbP, carboplatin plus paclitaxel; CG, cisplatin plus gemcitabine; GC, gemcitabine plus carboplatin.

cediranib-containing regimens treatment had improved overall survival.<sup>63</sup> These data strongly indicate that vascular normalization hypothesis theoretically and practically improves anomalous tumor vascular state. It makes the blood flow more uniform with subsequent increased uptake of cytotoxic drugs and oxygen, which result in better combined treatment outcome. There is no denying that “vascular normalization” theory is not universally recognized. A study indicated a rapid and significant reduction in perfusion and uptake of docetaxel in non-small-cell lung cancer after administration of bevacizumab.<sup>64</sup> However, this study did not look at the time course of perfusion or drug uptake and did not concern the patients’ survival benefit after treatment. Meanwhile, these patients were treated with the single dose of 15 mg/kg, and this study also did not examine whether a lower dose of bevacizumab had a diverse result. Thus, the optimal dose and scheduling of anti-VEGF agents are not yet clearly defined for the combined regimens in cancer patients. A crucial need remains for substantial research of therapeutic regimen and individual heterogeneity to support the vascular normalization theory.

## The hypothesis

Given the fact that hypercoagulable state and aberrant angiogenesis play significant roles in tumor microenvironment, we proposed combining two therapeutic strategies, anticoagulant and antiangiogenic therapy, to improve tumor patient prognosis by enhancing vessel perfusion, drug delivery, and oxygenation (Figure 1). As is shown earlier, inadequate intratumor perfusion could mainly result from two aspects. On one hand, intravascular and extravascular thrombi reduce effective cross-sectional area of tumor blood vessels. On the other hand, vessel hyperpermeability and tortuosity reduce blood flow rates in tumors because of excessive fluid loss and vessel resistance. Thus, anticoagulation strategy is based on the following progression of occurrence: solve previously existing thrombi, alleviate stress levels, enlarge vessel diameter, reopen restricted vessels, improve perfusion, and maximally result in enhanced drug delivery and oxygenation. Furthermore, the significant role of prevention and treatment of cancer-associated thrombosis and potential anticancer effects necessitates applying anticoagulant therapy clinically. Vascular normalization



**Figure 1** Strategies to enhance blood vessel perfusion and drug penetration.

**Notes:** Anticoagulant treatment depletes the deposition of fibrin or other plasma proteins on the blood vessel wall and the extravascular thrombosis, which increases the effective cross-sectional area of tumor blood vessels and improves perfusion. Vascular normalization remodels tumor vessels, which decreases vessel permeability and improves perfusion. Both strategies can be applied either alone or in combination based on whether tumor blood is hypercoagulable, vessels are aberrant, both of these, or neither.

**Abbreviations:** EC, endothelial cell; BM, basement membrane; PC, pericyte.

alters the monstrous vasculature phenotype to a relatively functional phenotype, as normal blood vessels. By using judicious dose and scheduling of antiangiogenic agents, tumor vessels restore relatively mature hierarchical structure and reduce blood content leakiness. Consequently, the interstitial fluid pressure and blood viscosity are recovered, which increase drug delivery and oxygen transport. However, the vascular normalization effect is transient. Unreasonable application of anti-VEGF treatment, including larger dose or longer duration, may destroy present vascular system, generate compensatory angiogenesis signaling pathways, and even facilitate primary tumor dissemination to distant organs.<sup>65,66</sup> In brief, anticoagulant and antiangiogenic therapy alleviate the problem of tumor perfusion abnormality from respective angles. Anticoagulant therapy improves abnormal high-coagulate blood, while antiangiogenic therapy modifies aberrant angiogenesis by vascular normalization. Thromboembolic events, especially arterial thrombosis, are remarkable adverse effects of VEGF inhibitors. A pooled analysis of five randomized trials indicated that addition of bevacizumab to chemotherapy was associated with a twofold increase in arterial thromboembolic events (ATEs) compared with chemotherapy alone (3.8% vs 1.7%;  $P=0.031$ ). The enhancement was further aggravated in elderly patients or those with a history of ATEs.<sup>67</sup> Thus, it is acceptable to use anticoagulant drugs as standard care in reducing the risk of ATEs in terms of VEGF inhibitors. Notably, the risk of bleeding is raised in patients treated with both anticoagulant and VEGF-targeted drugs.<sup>68</sup> The hemorrhage symptoms range from moderate mucocutaneous bleeding to fatal tumor-related bleeding. Combining the two agents with chemotherapy can further increase the incidence

and severity of bleeding events. It is essential that each patient should undergo elaborate risk–benefit assessment and management. Particular attention must be paid to those patients with risk factors, or with a history of bleeding. The effective benefit of the two strategies depends on the tumor microenvironment and particularly on whether tumor blood is hypercoagulable, vessels are aberrant, both of these, or neither. Thus, the paradigms that underlie anticoagulant and vascular normalization strategies are still open for improvement. We should consider the pathological process of tumor cells of every patient.

## Conclusion

The tumor microenvironment is entirely antithetical to normal tissues, characterized by prothrombotic state, monstrous vasculature structure, and low perfusion rates. In order to gain better oncotherapy efficiency, we need to get the abnormal tumor microenvironment back on track. In this article, we hypothesized that two complementary therapeutic strategies, the recuperation of hypercoagulable state with anticoagulant therapy and the normalization of the tumor vessel with anti-VEGF agents, may be ideal candidate methods that normalize the tumor microenvironment. Though the direct evidence in support of therapeutic benefits of vascular normalization and anticoagulation in cancer is insufficient, it provides a novel perspective into the complex pharmacokinetic and pharmacodynamic impact and interactions between hemodynamics and antitumor agent transportation. Thus, many questions remain to be explained, and more preclinical evidence is needed to support the paradigm. Scientific guidelines for the judicious application of these therapeutic strategies are necessary, given the high heterogeneity of patient constitution,

tumor nature, and the differences between primary tumors and metastases. We hope that this new strategy could yield a breakthrough that results in fluent tumor vessel perfusion and drug delivery and finally improves the outcomes of cancer patients.

## Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant No 81374014), Zhejiang Provincial Medical and Healthy Science and Technology Projects (Grant No 2013KYA228), Zhejiang Provincial Science and Technology Project (Grant No 2013C33112), Science Research Fund of Taizhou (Grant Nos A121KY08, A131KY13-3, and A131KY13-12), and Enze Medical Research Fund (Grant Nos 12EZA1, 13EZA2, and 13EZB6).

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Nagy JA, Brown LF, Senger DR, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. *Biochim Biophys Acta*. 1989;948(3):305–326.
- Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. *Blood*. 2007;110(6):1723–1729.
- Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. *J Clin Oncol*. 2009;27(29):4839–4847.
- Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. *Blood*. 1983;62(1):14–31.
- Khorana AA. Venous thromboembolism and prognosis in cancer. *Thromb Res*. 2010;125(6):490–493.
- Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. *Arch Intern Med*. 2004;164(15):1653–1661.
- Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. *Mol Aspects Med*. 2011;32(2):88–111.
- Kasper S, Schuler M. Targeted therapies in gastroesophageal cancer. *Eur J Cancer*. 2014;50(7):1247–1258.
- Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. *J Thromb Haemost*. 2004;2(8):1266–1271.
- Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). *J Clin Oncol*. 2004;22(10):1944–1948.
- Lecumberri R, López Vivanco G, Font A, et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. *Thromb Res*. 2013;132(6):666–670.
- Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. *Cancer*. 1994;74(1):38–45.
- Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. *Circulation*. 2003;107(23 suppl 1):I17–I21.
- Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. *Blood*. 2013;122(10):1712–1723.
- Young A, Chapman O, Connor C, Poole C, Rose P, Kakkar AK. Thrombosis and cancer. *Nat Rev Clin Oncol*. 2012;9(8):437–449.
- Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. *Cancer*. 2007;110(10):2339–2346.
- Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. *PLoS Med*. 2012;9(7):e1001275.
- Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. *JAMA*. 2005;293(6):715–722.
- Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. *Arch Intern Med*. 2006;166(4):458–464.
- Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. *J Thromb Haemost*. 2007;5(3):632–634.
- Kahn SR, Lim W, Dunn AS, et al; American College of Chest Physicians. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 suppl):195S–226S.
- Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. *Ann Oncol*. 2010;21(suppl5):v274–v276.
- Lyman GH, Khorana AA, Kuderer NM, et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2013;31(17):2189–2204.
- Streiff MB; National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. *Thromb Res*. 2010;125(suppl 2):S128–S133.
- Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. *Thromb Res*. 2014;134(6):1214–1219.
- Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. *Ann Intern Med*. 1999;130(10):789–799.
- Falanga A, Vignoli A, Diani E, Marchetti M. Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. *Patient Relat Outcome Meas*. 2011;2:175–188.
- Büller HR, Davidson BL, Decousus H, et al; Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. *N Engl J Med*. 2003;349(18):1695–1702.
- Brighton TA, Eikelboom JW, Mann K, et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. *N Engl J Med*. 2012;367(21):1979–1987.
- Connolly GC, Phipps RP, Francis CW. Platelets and cancer-associated thrombosis. *Semin Oncol*. 2014;41(3):302–310.
- Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. *Neoplasia*. 2002;4(6):465–473.
- Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. *Best Pract Res Clin Haematol*. 2009;22(1):49–60.
- Klementsen B, Jørgensen L. Mechanisms involved in the early interaction between HeLa cells, platelets and endothelial cells in vitro under the influence of thrombin. Effects of acetylsalicylic acid and Na-salicylate. *APMIS*. 1997;105(5):391–401.
- Horowitz NA, Blevins EA, Miller WM, et al. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. *Blood*. 2011;118(10):2889–2895.



35. Goerner A. The influence of anticlotting agents on transplantation and growth of tumor tissue. *J Lab Clin Med*. 1931;16(4):369–372.
36. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. *J Thromb Haemost*. 2013;11(2):223–233.
37. Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. *Semin Thromb Hemost*. 2007;33(7):688–694.
38. Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. *Thromb Haemost*. 2004;92(3):627–633.
39. Norrby K. Low-molecular-weight heparins and angiogenesis. *APMIS*. 2006;114(2):79–102.
40. McCowan C, Munro AJ, Donnan PT, Steele RJ. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. *Eur J Cancer*. 2013;49(5):1049–1057.
41. Ishikawa H, Mutoh M, Suzuki S, et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. *Gut*. 2014;63(11):1755–1759.
42. Paolino M, Choidas A, Wallner S, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. *Nature*. 2014;507(7493):508–512.
43. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. *Cancer Res*. 2002;62(18):5381–5385.
44. Phillips PG, Yalcin M, Cui H, et al. Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. *Anticancer Res*. 2011;31(2):411–419.
45. Carmeliet P. Angiogenesis in health and disease. *Nat Med*. 2003;9(6):653–660.
46. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. *Curr Opin Genet Dev*. 2005;15(1):102–111.
47. Sun C, Jain RK, Munn LL. Non-uniform plasma leakage affects local hematocrit and blood flow: implications for inflammation and tumor perfusion. *Ann Biomed Eng*. 2007;35(12):2121–2129.
48. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. *Nat Rev Clin Oncol*. 2010;7(11):653–664.
49. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. *Cancer Metastasis Rev*. 2007;26(2):241–248.
50. Hamzah J, Jugold M, Kiessling F, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. *Nature*. 2008;453(7193):410–414.
51. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med*. 1971;285(21):1182–1186.
52. Ferrara N. VEGF and the quest for tumour angiogenesis factors. *Nat Rev Cancer*. 2002;2(10):795–803.
53. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med*. 2004;350(23):2335–2342.
54. Koo PJ, Morgensztern D, Boyer JL, et al. Targeting vascular endothelial growth factor in patients with squamous cell lung cancer. *J Clin Oncol*. 2012;30(10):1137–1139.
55. Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. *Lancet*. Epub 2016 Feb 4.
56. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. *Nat Rev Cancer*. 2008;8(8):579–591.
57. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. *Cancer Cell*. 2003;3(4):347–361.
58. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. *Nat Med*. 2001;7(9):987–989.
59. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. *Physiol Rev*. 2011;91(3):1071–1121.
60. Jain RK, Martin JD, Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. *Annu Rev Biomed Eng*. 2014;16:321–346.
61. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? *Science*. 2006;312(5777):1171–1175.
62. Chatterjee S, Wiczorek C, Schöttle J, et al. Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer. *Cancer Res*. 2014;74(10):2816–2824.
63. Batchelor TT, Gerstner ER, Emblem KE, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. *Proc Natl Acad Sci U S A*. 2013;110(47):19059–19064.
64. Van der Veldt AA, Lubberink M, Bahce I, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. *Cancer Cell*. 2012;21(1):82–91.
65. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. *Cancer Cell*. 2009;15(3):220–231.
66. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nat Rev Drug Discov*. 2011;10(6):417–427.
67. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. *J Natl Cancer Inst*. 2007;99(16):1232–1239.
68. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. *Nat Rev Clin Oncol*. 2009;6(8):465–477.
69. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. *J Clin Oncol*. 2005;23(10):2130–2135.
70. van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. *J Clin Oncol*. 2011;29(15):2071–2076.
71. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. *N Engl J Med*. 2012;366(7):601–609.
72. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol*. 2008;26(12):2013–2019.
73. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol*. 2007;25(12):1539–1544.
74. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol*. 2012;30(28):3499–3506.
75. Tabernero J, Yoshino T, Cohn AL, et al; RAISE Study Investigators. Ramucicromab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol*. 2015;16(5):499–508.
76. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med*. 2006;355(24):2542–2550.
77. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol*. 2009;27(8):1227–1234.
78. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). *J Clin Oncol*. 2013;31(24):3004–3011.

79. Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or Placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. *J Clin Oncol*. 2015;33(19):2197–2204.
80. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. *J Clin Oncol*. 2014; 32(13):1302–1308.
81. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Clin Oncol*. 2012;30(17):2039–2045.
82. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. *J Clin Oncol*. 2011;29(30):3968–3976.
83. Wilke H, Muro K, Van Cutsem E, et al; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol*. 2014;15(11):1224–1235.

## OncoTargets and Therapy

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

Dovepress

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.